Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02300961 · ClinicalTrials.gov registry record · NA

Feasibility Neurocognitive Outcome After Transplant

A NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer, sponsored by Stanford University.

Active
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT02300961 is a NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 17 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02300961, a NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.

Interventions

  • BEHAVIORAL Cognitive rehabilitation program

Study Locations (1)

California

  • Stanford University, School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2014-12-01
Est. Completion 2025-11
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT02300961

The ClinicalTrials.gov registry entry for NCT02300961 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Cognitive rehabilitation program is the first listed.

NCT02300961 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02300961 about?

NCT02300961 is a clinical study titled "Feasibility Neurocognitive Outcome After Transplant". This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.

What is the current status of trial NCT02300961?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2014-12-01. Estimated completion is 2025-11.

What conditions does trial NCT02300961 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Pediatric Cancer, Stem Cell Transplantation.

What interventions are being tested in trial NCT02300961?

The interventions under investigation include: Cognitive rehabilitation program (BEHAVIORAL).

Who is sponsoring clinical trial NCT02300961?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02300961 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.